2 active not recruiting, 2 completed, 1 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow HER2-Positive Breast Carcinoma: new trials by email Literature Review of HER2-Positive Breast Carcinoma trials Research Report on HER2-Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 235 | 2023-05-10 | 2026-10-19 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-11-05 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery - HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 143 | 2012-12-06 | 2023-10-17 |
Breast Neoplasms (3) · Brain Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adnexal Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Magnetic Resonance Spectroscopy (3) · Biopsy (2) · CT-P6 (2) · Ogivri (2) · Ontruzant (2) · PF-05280014 (2) · Specimen Handling (2) · Trastuzumab (2) · trastuzumab biosimilar HLX02 (2) · 2C4 antibody (1) · Anastrozole (1) · Disulfides (1) · Drug Therapy (1) · Fluorodeoxyglucose F18 (1) · Fulvestrant (1)
National Cancer Institute (NCI) (3) · ECOG-ACRIN Cancer Research Group (1) · Mayo Clinic (1)
United States (5) · Canada (1) · Puerto Rico (1) · South Korea (1)
A P Chen (1) · Heather Jacene (1) · In A Kim (1) · Senthilkumar Damodaran (1) · Tufia C. Haddad, M.D. (1)
U10CA021661 (1), U10CA180820 (1), U10CA180868 (1), UM1CA186688 (1)